The top 10 targets in both figures were RAC-alpha serine/threonine-protein kinase (AKT1), tumor necrosis factor (TNF), interleukin-6 (IL6), interleukin-1 beta (IL1B), insulin (INS), cellular tumor antigen p53 (TP53), transcription factor AP-1(JUN), matrix metalloproteinase-9 (MMP9), caspase-3 (CASP3), and prostaglandin G/H synthase 2 (PTGS2), which suggested that these targets were the core targets of XJDHT for the treatment of SLE. This evidence concerns the gene TNF and systemic lupus erythematosus.